("TRHC") (NASDAQ:TRHC) today announced the organizations have partnered to provide TRHC's market-leading Bayesian Dosing platform, DoseMeRx™, to pharmacy professionals in small and rural hospitals. TRHC's DoseMeRx is the most efficient and cost-effective means for small and rural hospitals to comply with the revised guideline for monitoring vancomycin in the treatment of serious methicillin-resistant Staphylococcus aureus (MRSA) infections. In March 2020, the consensus vancomycin dosing guidelines from four leading pharmacy and infectious diseases professional societies – ASHP, Infectious Disease Society of America, Pediatric Infectious Disease Society, and Society of Infectious Disease Pharmacists – were published online in the American Journal of Health-System Pharmacy (AJHP). One of the biggest changes was the recommendation to move away from trough-based dosing to Area Under the Curve (AUC)-based monitoring and dosing of vancomycin in adults and children who have suspected or definitive MRSA infections.